News
AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average ...
FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...
Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the debut of a powerful new ...
The START Center for Cancer Research ("START"), the world's largest early-phase community-based cancer trial site network, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback